Sarepta Therapeutics, Inc. (BVMF:S1RP34)

Market Cap	10.99B -80.5%
Revenue (ttm)	12.11B +15.6%
Net Income	-3.93B
EPS	-39.27
Shares Out	n/a
PE Ratio	n/a
Forward PE	4.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	110
Average Volume	3,055
Open	5.60
Previous Close	5.73
Day's Range	5.21 - 5.60
52-Week Range	2.88 - 20.42
Beta	0.46
RSI	65.22
Earnings Date	May 6, 2026

About Sarepta Therapeutics

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1980
• Employees: 835
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: S1RP34

Financial Performance

Financial numbers in USD